Zhengye biotechnology holding limited announces full exercise of underwriters' over-allotment option

Jilin, china, jan. 14, 2025 (globe newswire) -- zhengye biotechnology holding limited (nasdaq: zybt) (the "company" or "zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccine in china, today announced that the underwriter of its initial public offering (the "offering") have exercised in full their option to purchase an additional 225,000 ordinary shares at a public offering price of $4.00 per ordinary share to cover over-allotments. gross proceeds of the company's initial public offering, including the exercise of the over-allotment, totaled $6.9 million, before deducting underwriting discounts and other related expenses. the ordinary shares began trading on the nasdaq capital market on january 7, 2025 under the ticker symbol “zybt.”
ZYBT Ratings Summary
ZYBT Quant Ranking